Clinical Trial Update: A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation

View source ↗

Summary

A prospective non-interventional study to evaluate clinical outcomes of ribociclib combined with endocrine therapy in elderly patients with HR-positive, HER2-ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hr-positive Advanced Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: HR+HER2- Advanced Breast Cancer | Status: ACTIVE_NOT_RECRUITING